The FDA recently issued two draft guidances on the use of social medial by pharmaceutical and biotechnology companies. One focuses on presenting risk-and-benefit information for drugs or devices and the other offers advice for dealing with misinformation spread on third-party sites. (For more on this, click here.)

Poll Question:
Do you think the FDA needs to have as strict a stance on social media outlets as it does on traditional communication modes of regulatory information?



Previous articleLook Ma, No Reference Genome! A New Way to ID Species Lurking in Microbial Societies
Next articleConcept Life Sciences Charts Growth Path with Three Acquisitions